7 Numbers That Tell You If Your Clinical Trial Will Succeed

7 Numbers That Tell You If Your Clinical Trial Will Succeed

Published: July 23, 2026

‍

Three months into enrollment, the steering committee wants an update  and often what's on hand is an impression of how things are going, not hard evidence. One site seems slow. Query volume feels higher than last time. But an impression isn't a data point you can put in a board deck.

That's the gap clinical trial analytics is meant to close.

Trials have gotten harder to run: more sites, more decentralized elements, tighter regulatory expectations, and a flood of real-world data that few teams have the bandwidth to review manually. For years, the standard approach was to wait until database lock and then assess what happened  useful for the record, but too late to change the outcome.

The teams getting this right are watching a handful of metrics continuously, not just at the end. Here are seven worth paying attention to.

Why bother with prediction at all?

Because a clinical trial represents a significant investment of resources and patients' time, with real risk attached. Every week of delay compounds. Every dropout chips away at statistical power. Every protocol deviation is a compliance risk that can resurface during an audit.

The questions that matter mid-trial include:

• Are enrollment targets achievable on the current trajectory, or is the timeline at risk?
• Which sites need attention this week, not next quarter?
• Is the dropout rate quietly eating into statistical power?
• Are deviations clustering somewhere that points to a training gap?
• Where's the bottleneck nobody's raised in the last three status meetings?

Predictive analytics doesn't answer these with certainty, but it gives trial leads a far better basis for judgment than waiting to see.

1. Enrollment velocity

Total enrollment gets all the attention, but velocity and how fast participants are actually coming in  says more about where things are headed. A trial that's technically "on pace" today can still be in trouble if the rate is declining week over week.

Good analytics setups track:

• Enrollment trends by day and week
• How individual sites compare against each other
• Regional differences in recruitment
• A forecasted completion date, updated as new data comes in

Some platforms compare current pacing against historical trials to flag when a study is falling behind schedule, often before it's evident in status meetings.

Why care: Catching a slowdown early means there's still time to open new sites, adjust outreach, or shift resources  options that disappear once a study is six weeks from its enrollment deadline.

2. Screen failure rate

Not everyone who shows up for screening is going to qualify, and that's expected. But when the screen failure rate stays stubbornly high, it's usually a signal: inclusion criteria may be too narrow, pre-screening at certain sites may not be catching obvious disqualifiers, or recruitment may be targeting the wrong population entirely.

Why care: Fixing this isn't just about hitting numbers faster  it also means fewer wasted screening visits, lower costs, and a better experience for the people who volunteered their time.

3. Site performance score

Not all sites perform equally, and treat them as if they do waste monitoring effort. Some sites recruit fast and keep clean data. Others struggle with one or the other, or both.

Rather than judging a site on a single number, it's more useful to combine several signals:

• Recruitment rate
• Retention
• How fast queries get resolved
• Data quality
• Protocol compliance
• What monitors are flagging in visit reports

Why care: A composite score shows where to send support before a site becomes a real problem, and prevents over-monitoring sites that are already performing well.

4. Patient retention and dropout risk

Getting someone enrolled is only step one. Keeping them in the study is the harder part, and it matters more than people sometimes give it credit fordropout doesn't just shrink your sample, it can bias it.

Models built to flag dropout risk usually look at things like:

• Missed visits
• Engagement patterns
• Wearable or digital health data, where available
• Past adherence history
• Demographics
• How well a site is communicating with participants

Why care: If you can spot the participants drifting away before they actually leave, there's still a chance to intervenea call, a schedule adjustment, whatever it takes.

5. Protocol deviation trends

Deviations happen in basically every trial. The mistake is treating them as something to tally up at the end rather than watch as they occur. Real-time tracking can surface:

• Deviations that keep repeating
• Sites with recurring compliance issues
• Investigators who might need more training
• Specific protocol sections that keep tripping people up

Some dashboards go a step further and connect deviation patterns to patient outcomes and site scores, which is where things get genuinely useful.

Why care: Catching this early means fewer surprises during an audit and a stronger compliance story overall.

6. Data quality and query resolution

Between EDC systems, lab reports, imaging, wearables, and ePRO data, trials generate a genuinely overwhelming amount of information. Bad data doesn't announce itself it just sits there until someone hits it during statistical analysis, usually at the worst possible time.

Metrics worth watching:

• How many queries are being generated
• How long they take to resolve
• Percentage of missing data
• Delays in data entry
• Progress on source verification

Some tools also flag unusual patterns automatically, which helps prioritize which records actually need a human look.

Why care: Clean data means a faster path to database lock and fewer headaches during regulatory review.

7. The overall completion forecast

This is really the metric that ties everything else together. Rather than staring at six separate dashboards, the most useful analytics setups combine recruitment, retention, site performance, deviations, and data quality into one running estimate of "will this trial actually finish successfully."

That forecast updates as new data rolls in, and it's built to answer the questions that actually keep trial leads up at night:

• Are we going to finish on time?
• What's our real shot at hitting enrollment targets?
• What's the biggest risk to completion right now?
• Where should the next round of resources go?

Why care: Instead of finding out at the finish line whether the trial worked, you get a running view of trial health the whole way through.

Where AI actually fits into this

Rather than replacing judgment, AI is mostly good at spotting patterns across huge datasets faster than a person could, especially when you're looking across many trials at once. That shows up in things like:

• Flagging recruitment bottlenecks before they're obvious
• Helping pick better sites in the first place
• Catching dropout risk earlier
• Spotting data anomalies automatically
• Producing better timeline forecasts
• Supporting more adaptive trial designs

Used well, inside a properly secured clinical data environment, it lets teams make faster calls without cutting corners on data integrity or compliance.

The bottom line

Collecting data was never really the hard part. Turning it into something you can act on while the trial is still runningthat's the actual value. Sponsors and CROs that build this muscle catch problems earlier, keep patients engaged longer, and make decisions based on evidence instead of instinct.

As trials keep getting more complex, this kind of ongoing analytics isn't a nice-to-have anymore. It's becoming table stakes for running a study that finishes on time and holds up under scrutiny.

That combination of clinical fluency and technical depth is rarer than it should be, which is part of why teams like Reveal HealthTech, who pair clinical and product expertise with hands-on AI and cloud engineering on HIPAA-compliant infrastructure, tend to get pulled into these builds rather than a pure data-science shop or a dev team working alone. The trials that get this right aren't just collecting better data. They've got the right people translating it into action while there's still time to do something about it.

Frequently Asked Questions

What is predictive analytics in clinical trials?

Predictive analytics in clinical trials uses historical and real time trial data such as enrollment rates, site performance, data quality metrics and more to forecast outcomes like enrollment completion dates, dropout risk and overall trial success.

How does AI improve clinical trial monitoring?

AI is useful for spotting patterns across large datasets like flagging recruitment bottlenecks, predicting dropout risk, detecting data anomalies and improving timeline forecasts. It supports human judgement rather than replacing it, and works the best within a properly secured and HIPAA compliant clinical; data environment.

How is a clinical trial success determined?

Clinical trial success is judged on several levels at once: whether the primary endpoint was met with statistical and clinical significance, whether the safety profile stayed acceptable, whether enough clean data was collected to support a trustworthy analysis, whether the trial finished on time and within budget, and ultimately whether the results support regulatory approval.

Why does patient dropout matter beyond sample size?

Dropout can bias the results if the participants who leave differ systematically from those who stay, undermining statistical power and the validity of the final analysis. Predictive models that flag at-risk participants (based on missed visits, engagement patterns, or adherence history) allow for earlier intervention.

How can sponsors and CROs predict if a clinical trial will finish on time?

The most reliable approach combines multiple real-time signals enrollment velocity, retention, site performance, deviation trends, and data quality into a single completion forecast that updates as new data comes in, rather than relying on a static timeline set at trial launch.

‍

‍

‍

‍

‍

‍